Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The effects of weekly administration of 40 mg pegvisomant or placebo on quality of life and insulin sensitivity in acromegalic patients with normal IGF-I [insulin-like growth factor-I] concentrations during long-term treatment with long-acting somatostatin analogs

Trial Profile

The effects of weekly administration of 40 mg pegvisomant or placebo on quality of life and insulin sensitivity in acromegalic patients with normal IGF-I [insulin-like growth factor-I] concentrations during long-term treatment with long-acting somatostatin analogs

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Oct 2009

At a glance

  • Drugs Pegvisomant (Primary)
  • Indications Acromegaly
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 09 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top